Clinical analysis of TACE combined with RFA in treating primary liver cancers of high-risk sites

doi:10.3877/cma.j.issn.1674-3946.2020.02.027

Abstract

Abstract:

Objective

To investigate the clinical effect of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in the treatment of primary liver cancers of high-risk sites.

Methods

Clinical data of 100 patients with primary liver cancers of high-risk sites from April 2013 to April 2018 were analyzed retrospectively. According to different therapeutic treatments, 100 patients were divided into TACE group (50 cases) and Combined group (50 cases). Patients in TACE group received TACE, while patients in Combined group underwent both TACE and RFA. Statistical analysis were performed by using SPSS18.0 software. Count data such as 1-year survival rate, short-term outcome and postoperative complications were analyzed by using χ² test. Measurement data such as AFP and KPS were represented as (±s) and were examined by using t test. A P value of < 0.05 was considered as statistical significant difference.

Results

Short-term curative effect in Combined group was significantly higher than that in TACE group (P<0.05), and the one-year survival rate of 77.9% in combined group was significantly higher than that 54.6% in TACE group (P<0.05). There was no significant difference between two groups in terms of AFP and KPS before operation (P>0.05). After operation, AFP in Combined group was much lower than that in TACE group (P<0.05), while KPS in Combined group was much higher than that in TACE group (P<0.05). The incidence of abdominal pain in Combined group was higher than that in TACE group (P<0.05), however other adverse reactions were lower than those in TACE group respectively (P<0.05).

Conclusion

TACE combined with RFA is better than TACE alone in the treatment of primary liver cancers of high-risk sites, with improved survival of the patients. The combined treatments have application value for patients with unresectable primary liver cancers, and it is worth of clinical promotion.

Key words: Carcinoma, hepatocellular, Hepatectomy, Ablation techniques, Transarterial embolization

Qiang Zhang, Hengping Li. Clinical analysis of TACE combined with RFA in treating primary liver cancers of high-risk sites[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2020, 14(02): 201-204.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhpwkssxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3946.2020.02.027

https://zhpwkssxzz.cma-cmc.com.cn/EN/Y2020/V14/I02/201

Figures/Tables 4

References 18

[1]	王健，佟小强，吕天石，等．肝动脉化疗栓塞术联合射频消融治疗肝内特殊部位恶性肿瘤[J]．中国微创外科杂志，2016，37(1)：9-12.
[2]	Gholamrezanezhad A，Mirpour S，Geschwind JF，et al.Evaluation of 70－150－μm doxorubicin－eluting beads for transcatheter arterial chemoembolization in the rabbit liver VX2 tumour model[J]．Eur Radiol，2016，26(10)：3474-3482.
[3]	高飞，庞志刚，韩斌，等．肝动脉化疗栓塞联合射频消融术治疗大肝癌的疗效及生存分析[J]．介入放射学杂志，2016，25(4)：316-319.
[4]	赵中伟，纪建松，邵国良，等．肝动脉化疗栓塞联合射频消融治疗包膜下肝癌的疗效和安全性[J]．中华放射学杂志，2016，50(5)：380-383.
[5]	Ako S，Nakamura S，Nouso K，et al.Transcatheter Arterial Chemoembolization to Reduce Size of Hepatocellular Carcinoma before Radiofrequency Ablation[J]．Acta Medica Okayama，2018，72(1)：47-52.
[6]	谢可平，邹嵩，曾艳，等．肝动脉栓塞联合射频消融术治疗肝癌的效果及护理配合[J]．中华肿瘤防治杂志，2016，21(S1)：331-332.
[7]	朱楠，鲁东，肖景坤，等．肝动脉化疗栓塞联合射频消融术治疗中晚期肝癌的疗效[J]．中国介入影像与治疗学，2017，14(4)：195-199.
[8]	Hashimoto S，Ogino H，Iwata H，et al.Proton Beam Therapy for Locally Recurrent Hepatocellular Carcinoma After Radiofrequency Ablation or Transcatheter Arterial Chemoembolization[J]．International Journal of Radiation Oncologybiologyphysics，2017，99(2)：S193-S194.
[9]	袁筑慧，王洋，李威．经皮射频消融术治疗外科切除术后复发性肝细胞癌疗效分析[J]．中国癌症杂志，2017，27(12)：959-963.
[10]	刘江伟，黄建钊，孙倩，等．射频消融术和手术治疗原发性肝癌对照分析[J]．中国医学计算机成像杂志，2016，22(5)：444-450.
[11]	陈兵，吴威．射频消融对原发性肝癌治疗评价及预后危险因素分析[J]．实用放射学杂志，2016，32(10)：1545-1548.
[12]	Kato K，Abe H，Ika M，et al.C－Arm Cone Beam Computed Tomography Guidance for Radiofrequency Ablation in Hepatocellular Carcinoma[J]．Oncology，2017，92(3)：142-152.
[13]	Zuo TY，Liu FY，Wang MQ，et al.TranscatheterArterialChemoembolizationCombinedwithSimultaneousComputedTomography－guidedRadiofrequencyAblationforLargeHepatocellularCarcinomas[J]．Chin Med J(Engl)，2017，130(22)：2666-2673.
[14]	王军，彭磊，崔海宁，等．射频消融及手术治疗不同大小小肝癌的无瘤生存率及复发转移率[J]．实用医学杂志，2016，32(17)：2851-2853.
[15]	方良毅，陈晓明，金浩生，等．多层螺旋CT多平面重建技术在肝癌射频消融术中的应用[J]．介入放射学杂志，2016，25(5)：425-430.
[16]	Liu H，Wang ZG，Fu SY，et al.Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria[J]．Br J Surg，2016，103(4)：348-356.
[17]	肖飞，胡波，宋亚锋．射频消融对比手术切除治疗小肝癌的Meta分析[J]．中华肿瘤防治杂志，2016，23(S2)：321-322.
[18]	Lv N，Kong Y，Mu L，et al.Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial[J]．Eur Radiol，2016，26(10)：3492-3499.

组别	例数	年龄	性别	Child－Pugh分级	肿瘤直径(cm)
组别	例数	[(±s)，岁]	男/女	A/B	>3/≤3
TACE组	50	54.5±4.2	30/20	39/11	28/22
联合组	50	54.9±4.3	28/22	40/10	27/23
t/χ²	/	1.654	2.468	1.847	2.498
P	/	>0.05	>0.05	>0.05	>0.05

组别	例数	年龄	性别	Child－Pugh分级	肿瘤直径(cm)
组别	例数	[(±s)，岁]	男/女	A/B	>3/≤3
TACE组	50	54.5±4.2	30/20	39/11	28/22
联合组	50	54.9±4.3	28/22	40/10	27/23
t/χ²	/	1.654	2.468	1.847	2.498
P	/	>0.05	>0.05	>0.05	>0.05

组别	例数	CR	PR	SD	PD	RR
TACE组	50	7(14.0)	20(40.0)	17(34.0)	6(12.0)	54.0%
联合组	50	16(32.0)	26(52.0)	6(12.9)	2(4.0)	84.0%
χ²	/	6.668	5.473	6.720	5.916	7.402
P	/	<0.05	<0.05	<0.05	<0.05	<0.05

组别	例数	CR	PR	SD	PD	RR
TACE组	50	7(14.0)	20(40.0)	17(34.0)	6(12.0)	54.0%
联合组	50	16(32.0)	26(52.0)	6(12.9)	2(4.0)	84.0%
χ²	/	6.668	5.473	6.720	5.916	7.402
P	/	<0.05	<0.05	<0.05	<0.05	<0.05

组别	例数	AFP(ng/ml)		KPS评分(分)
组别	例数	术前	术后	术前	术后
TACE组	50	423.5±93.2	168.2±68.4	64.2±3.1	70.4±4.1
联合组	50	432.7±90.8	114.3±53.9	63.6±3.0	88.6±3.1
t值	/	2.315	14.198	1.691	10.908
P值	/	>0.05	<0.05	>0.05	<0.05

Please choose a citation manager

Content to export